173 related articles for article (PubMed ID: 8746587)
1. Radiotherapy with carbogen breathing and nicotinamide in head and neck cancer: feasibility and toxicity.
Kaanders JH; Pop LA; Marres HA; van der Maazen RW; van der Kogel AJ; van Daal WA
Radiother Oncol; 1995 Dec; 37(3):190-8. PubMed ID: 8746587
[TBL] [Abstract][Full Text] [Related]
2. Accelerated radiotherapy with carbogen and nicotinamide (ARCON) for laryngeal cancer.
Kaanders JH; Pop LA; Marres HA; Liefers J; van den Hoogen FJ; van Daal WA; van der Kogel AJ
Radiother Oncol; 1998 Aug; 48(2):115-22. PubMed ID: 9783882
[TBL] [Abstract][Full Text] [Related]
3. Acute toxicity profile and compliance to accelerated radiotherapy plus carbogen and nicotinamide for clinical stage T2-4 laryngeal cancer: results of a phase III randomized trial.
Janssens GO; Terhaard CH; Doornaert PA; Bijl HP; van den Ende P; Chin A; Pop LA; Kaanders JH
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):532-8. PubMed ID: 21300447
[TBL] [Abstract][Full Text] [Related]
4. Acute effects of accelerated radiotherapy in combination with carbogen breathing and nicotinamide (ARCON).
Zackrisson B; Franzén L; Henriksson R; Littbrand B; Stratford M; Dennis M; Rojas AM; Denekamp J
Acta Oncol; 1994; 33(4):377-81. PubMed ID: 8018369
[TBL] [Abstract][Full Text] [Related]
5. Accelerated radiotherapy, carbogen and nicotinamide (ARCON) in locally advanced head and neck cancer: a feasibility study.
Saunders MI; Hoskin PJ; Pigott K; Powell ME; Goodchild K; Dische S; Denekamp J; Stratford MR; Dennis MF; Rojas AM
Radiother Oncol; 1997 Nov; 45(2):159-66. PubMed ID: 9424007
[TBL] [Abstract][Full Text] [Related]
6. Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: results of a phase III randomized trial.
Janssens GO; Rademakers SE; Terhaard CH; Doornaert PA; Bijl HP; van den Ende P; Chin A; Marres HA; de Bree R; van der Kogel AJ; Hoogsteen IJ; Bussink J; Span PN; Kaanders JH
J Clin Oncol; 2012 May; 30(15):1777-83. PubMed ID: 22508814
[TBL] [Abstract][Full Text] [Related]
7. ARCON: accelerated radiotherapy with carbogen and nicotinamide in non small cell lung cancer: a phase I/II study by the EORTC.
Bernier J; Denekamp J; Rojas A; Trovò M; Horiot JC; Hamers H; Antognoni P; Dahl O; Richaud P; Kaanders J; van Glabbeke M; Piérart M
Radiother Oncol; 1999 Aug; 52(2):149-56. PubMed ID: 10577700
[TBL] [Abstract][Full Text] [Related]
8. Carbogen breathing combined with radical radiotherapy in advanced head and neck cancer patients with severe co-morbidities.
Vees H; Allal AS
Clin Oncol (R Coll Radiol); 2006 Aug; 18(6):493-6. PubMed ID: 16909974
[TBL] [Abstract][Full Text] [Related]
9. Accelerated radiotherapy, carbogen, and nicotinamide in glioblastoma multiforme: report of European Organization for Research and Treatment of Cancer trial 22933.
Miralbell R; Mornex F; Greiner R; Bolla M; Storme G; Hulshof M; Bernier J; Denekamp J; Rojas AM; Pierart M; van Glabbeke M; Mirimanoff RO
J Clin Oncol; 1999 Oct; 17(10):3143-9. PubMed ID: 10506611
[TBL] [Abstract][Full Text] [Related]
10. ARCON: experience in 215 patients with advanced head-and-neck cancer.
Kaanders JH; Pop LA; Marres HA; Bruaset I; van den Hoogen FJ; Merkx MA; van der Kogel AJ
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):769-78. PubMed ID: 11849800
[TBL] [Abstract][Full Text] [Related]
11. Tolerance of nicotinamide and carbogen with radiation therapy for glioblastoma.
Pickles T; Graham P; Syndikus I; Rheaume DE; Duncan GG; Green A; Marlow C
Radiother Oncol; 1996 Sep; 40(3):245-7. PubMed ID: 8940752
[TBL] [Abstract][Full Text] [Related]
12. ARCON: accelerated radiotherapy with carbogen and nicotinamide in head and neck squamous cell carcinomas. The experience of the Co-operative group of radiotherapy of the european organization for research and treatment of cancer (EORTC).
Bernier J; Denekamp J; Rojas A; Minatel E; Horiot J; Hamers H; Antognoni P; Dahl O; Richaud P; van Glabbeke M; Piérart M
Radiother Oncol; 2000 May; 55(2):111-9. PubMed ID: 10799722
[TBL] [Abstract][Full Text] [Related]
13. Preclinical studies on how to deal with patient intolerance to nicotinamide and carbogen.
Horsman MR; Overgaard J
Radiother Oncol; 2004 Mar; 70(3):301-9. PubMed ID: 15064017
[TBL] [Abstract][Full Text] [Related]
14. Conventional radiotherapy combined with carbogen breathing and nicotinamide for malignant gliomas.
van der Maazen RW; Thijssen HO; Kaanders JH; de Koster A; Keyser A; Prick MJ; Grotenhuis JA; Wesseling P; van der Kogel AJ
Radiother Oncol; 1995 May; 35(2):118-22. PubMed ID: 7569019
[TBL] [Abstract][Full Text] [Related]
15. Radiosensitisation in normal tissues with oxygen, carbogen or nicotinamide: therapeutic gain comparisons for fractionated x-ray schedules.
Rojas A; Vojnovic B; Johns H; Joiner MC; Martindale C; Fowler JF; Denekamp J
Radiother Oncol; 1996 Apr; 39(1):53-64. PubMed ID: 8735494
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the effectiveness of tirapazamine and carbogen with nicotinamide in enhancing the response of a human tumor xenograft to fractionated irradiation.
el-Said A; Menke D; Dorie MJ; Brown JM
Radiat Oncol Investig; 1999; 7(3):163-9. PubMed ID: 10406058
[TBL] [Abstract][Full Text] [Related]
17. Carbogen and nicotinamide as radiosensitizers in a murine mammary carcinoma using conventional and accelerated radiotherapy.
Rojas A; Hirst VK; Calvert AS; Johns H
Int J Radiat Oncol Biol Phys; 1996 Jan; 34(2):357-65. PubMed ID: 8567336
[TBL] [Abstract][Full Text] [Related]
18. Hypoxic radiosensitizers in radical radiotherapy for patients with bladder carcinoma: hyperbaric oxygen, misonidazole, and accelerated radiotherapy, carbogen, and nicotinamide.
Hoskin PJ; Saunders MI; Dische S
Cancer; 1999 Oct; 86(7):1322-8. PubMed ID: 10506720
[TBL] [Abstract][Full Text] [Related]
19. Oxygen-modifying treatment with ARCON reduces the prognostic significance of hemoglobin in squamous cell carcinoma of the head and neck.
Hoogsteen IJ; Pop LA; Marres HA; Merkx MA; van den Hoogen FJ; van der Kogel AJ; Kaanders JH
Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):83-9. PubMed ID: 16213107
[TBL] [Abstract][Full Text] [Related]
20. A dose escalation study with intensity modulated radiation therapy (IMRT) in T2N0, T2N1, T3N0 squamous cell carcinomas (SCC) of the oropharynx, larynx and hypopharynx using a simultaneous integrated boost (SIB) approach.
Leclerc M; Maingon P; Hamoir M; Dalban C; Calais G; Nuyts S; Serre A; Grégoire V
Radiother Oncol; 2013 Mar; 106(3):333-40. PubMed ID: 23541643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
